TY - JOUR
T1 - Sumatriptan (50 mg tablets vs. 25 mg suppositories) in the acute treatment of menstrually related migraine and oral contraceptive-induced menstrual migraine
T2 - A pilot study
AU - Facchinetti, Fabio
AU - Allais, Gianni
AU - Nappi, Rossella E.
AU - Gabellari, Ilaria Castagnoli
AU - Di Renzo, Gian Carlo
AU - Genazzani, Andrea R.
AU - Bellafronte, Manuela
AU - Roncolato, Maurizio
AU - Benedetto, Chiara
PY - 2010/10
Y1 - 2010/10
N2 - Migraine attacks are common in the perimenstrual period (menstrually-related migraine, MRM) and can be particularly exacerbated by the cyclic suspension of oral contraceptives (oral contraceptive-induced menstrual migraine, OCMM). This cross-over, randomised study evaluated the efficacy and tolerability of rectal (25mg) and oral (50mg) sumatriptan in the treatment of 232 menstrual migraine attacks (135 MRM and 97 OCMM). Two hours after suppository administration, 72 of patients in the MRM group achieved pain relief and 24 were pain free; after tablet administration, the percentages were 66 and 27, respectively. In the OCMM group 55 of patients improved at 2h with suppositories and 46 with tablets, 27 of patients were pain-free after suppositories and 18 after tablets. Fifty percent of patients given suppositories were pain-free at 4h post-treatment and 47 of those given tablets. Sumatriptan also effectively alleviated symptoms associated with migraine, such as nausea, vomiting and photo/phonophobia. A single dose of medication sufficed for pain relief without relapse in 47.4 of the attacks (MRM: 66; OCMM: 33). Both formulations were well tolerated.
AB - Migraine attacks are common in the perimenstrual period (menstrually-related migraine, MRM) and can be particularly exacerbated by the cyclic suspension of oral contraceptives (oral contraceptive-induced menstrual migraine, OCMM). This cross-over, randomised study evaluated the efficacy and tolerability of rectal (25mg) and oral (50mg) sumatriptan in the treatment of 232 menstrual migraine attacks (135 MRM and 97 OCMM). Two hours after suppository administration, 72 of patients in the MRM group achieved pain relief and 24 were pain free; after tablet administration, the percentages were 66 and 27, respectively. In the OCMM group 55 of patients improved at 2h with suppositories and 46 with tablets, 27 of patients were pain-free after suppositories and 18 after tablets. Fifty percent of patients given suppositories were pain-free at 4h post-treatment and 47 of those given tablets. Sumatriptan also effectively alleviated symptoms associated with migraine, such as nausea, vomiting and photo/phonophobia. A single dose of medication sufficed for pain relief without relapse in 47.4 of the attacks (MRM: 66; OCMM: 33). Both formulations were well tolerated.
KW - Acute treatment
KW - menstrual migraine
KW - oral contraceptives
KW - sumatriptan
UR - http://www.scopus.com/inward/record.url?scp=77956515617&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956515617&partnerID=8YFLogxK
U2 - 10.3109/09513590.2010.487607
DO - 10.3109/09513590.2010.487607
M3 - Article
C2 - 20528213
AN - SCOPUS:77956515617
VL - 26
SP - 773
EP - 779
JO - Gynecological Endocrinology
JF - Gynecological Endocrinology
SN - 0951-3590
IS - 10
ER -